https://www.wsj.com/articles/fda-widens-path-for-rare-disease-treatments-with-new-approval-1ba99c09
The company said it plans to charge $370,000 a year for the drug and that through insurance and a patient-assistance program, patients should be able to gain access.
Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-149
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.16 |
Change
0.025(0.19%) |
Mkt cap ! $1.683B | |||
| Open | High | Low | Value | Volume |
| $13.22 | $13.32 | $13.01 | $1.381M | 105.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 41 | $13.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.16 | 738 | 12 |
View Market Depth
| Last trade - 11.55am 21/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |